VR 942

Drug Profile

VR 942

Alternative Names: Immunomodulatory biologic - respiratory disease - UCB/Vectura; UCB 4144; VR942

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator UCB; Vectura
  • Class Antiasthmatics; Biological factors
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Asthma

Most Recent Events

  • 04 Jan 2018 VR 942 is available for licensing as of 04 Jan 2018. www.vectura.com
  • 21 Mar 2017 Vectura plans a phase II trial in Asthma
  • 01 Apr 2016 Venctura completed a phase I trial for Asthma (In volunteers) in United Kingdom (NCT02473939)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top